ArticleBiology2023

Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk.

Maria Antonella Zingaropoli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.